Important Safety Information    Please click here for full Prescribing Information PHN Therapy Can Star Here

Chicken Pox Father and sonPostherpetic Neuralgia (PHN): An Overview

Herpes zoster (shingles) and the potential sequela (PHN) are caused by the same virus that causes chicken pox1,2

Chicken pox is the primary risk factor for shingles and subsequent postherpetic neuralgia (PHN) pain1,2

  • 95% of Americans have had chicken pox1
  • Approximately 1 million new cases of herpes zoster (HZ; shingles) in the United States each year1,2
  • HZ can occur at any age
  • Incidence increases with age3
  • Approximately 120,000 to 200,000 PHN cases annually in the United States1


  • For patients <27 year of age, a population-based study by Hope-Simpson found that none of the patients who developed herpes zoster experienced PHN. For patients between the ages of 50 and 59, the incidence was 7.4%; however, that number nearly tripled for patients in the 60-69 age group and continued to increase in subsequent decades. By the age of 80, over a third of patients diagnosed with shingles went on to develop PHN16
  • Risk factors include: presence of a prodrome, severe acute pain, severe HZ rash within 3 days of HZ infection2,4

shinglesShingles Causes and Symptoms

Shingles, or herpes zoster, is a disease caused by reactivation of the varicella zoster virus (VZV) that has remained dormant in the dorsal root ganglia following a prior systemic VZV infection, such as chicken pox.10






PHN Management Postherpetic Neuralgia (PHN)

There are varying opinions as to how much time must elapse following acute zoster outbreaks before pain is definitively termed postherpetic neuralgia (PHN); however PHN is commonly defined as pain that persists or occurs at least one month after acute herpes zoster.10,11


Online Resources

Learning more about after-shingles pain is as easy as 1, 2, 3... you can visit the LIDODERM® Online Resource Page for additional information.

References

  1. Cluff RS, Rowbotham MC. Pain Caused by Herpes Zoster Infection. Neurol Clin. 1998;16(4):813-832.
  2. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc.
  3. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-753.
  4. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62(9):1545-1551.
  5. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(suppl 9):S17-S25.
  6. Panlilio LM, Christo PJ, Raja SN. Current Management of Postherpetic Neuralgia. Neurologist. 2002;8:339-350.
  7. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. J Am Geriatr Soc. 2007;55(8):1168-1175.
  8. Rowbotham MC. Postherpetic neuralgia. Semin Neurol. 1994;14(3):247-254. 2007;107(suppl 1):S2-S7.
  9. Shingles: hope through research. National Institute of Neurological Disorders and Stroke. National Institutes of Health Web site. http://www.ninds.nih.gov/disorders/shingles/detail_shingles.htm?css=print. Accessed October 12, 2007.
  10. Kost RG, Straus SE. Postherpetic Neuralgia – Pathogenesis, Treatment, and Prevention. N Engl J Med. 1996;335:32-42.
  11. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246-253.
  12. Wallace MS, Oxman MN. Anesthesiol Clin N Am. 1997;15.
  13. Fields HL, Rowbotham MC, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5(4):209-227.
  14. Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today's Therapeutic Trends. 2000;18:1-20.
  15. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959-1964.
  16. Hope-Simpson, R.E. Herpes Zoster in General Practice: Postherpetic Neuralgia. Journal of the Royal College of General Practitioners. 1975; 25: 571-575.

You are now leaving the Lidoderm.com website and moving to an external website independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.

If you do not wish to leave this site, click Cancel. Click OK to continue.

Intended for US Residents Only
LIDODERM® Home | LIDODERM® HCP Home | About After-Shingles Pain (PHN) | Pain Assessment Tool & Checklist
About the LIDODERM® Patch | Resources | Important Safety Information | Prescribing Information
Signup for Email Updates | Privacy/Legal | Site Map | Contact Us


© 2011 Endo Pharmaceuticals. All rights reserved.
LIDODERM® is a registered trademark of Hind Health Care, Inc.
LD-01580/September 2011
rx_only